StockMacro
Menu

PROCEPT BioRobotics

$24.70 -10% in 6 monthsMarket cap $1.4B

PRCT on XNAS, Health Care, PROCEPT BioRobotics Corporation, job postings

Measures activity, not value. Not investment advice.

Quarterly revenue rose 18% to $98.3M while the stock jumped 35% in one month.

  • BadInstitutional holders fell 8.4%, from 250 filers to 229
  • BadFree cash outflow of $85.1M over 12 months despite 17% revenue growth

Written by AI from the data on this page, 22 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. The company develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.

Industry
Surgical & medical instruments & apparatus (Health Care)
Employees
888
Website
procept-biorobotics.com
Listed
Nasdaq, US
Last results
4 Nov 2026
Next results
expected around 24 Feb 2027 (an estimate: a year ago it reported on 25 Feb 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $98.3M, net loss $26.5M.
Quarter to 31 Dec 2021: revenue $10.1M, net income -$18.3MQuarter to 31 Dec 2021: revenue $10.1M, net income -$18.3MQuarter to 31 Mar 2022: revenue $14.2M, net income -$17.2MQuarter to 31 Mar 2022: revenue $14.2M, net income -$17.2MQuarter to 30 Jun 2022: revenue $16.7M, net income -$19.2MQuarter to 30 Jun 2022: revenue $16.7M, net income -$19.2MQuarter to 30 Sep 2022: revenue $20.3M, net income -$22.6MQuarter to 30 Sep 2022: revenue $20.3M, net income -$22.6MQuarter to 31 Dec 2022: revenue $23.8M, net income -$28.2MQuarter to 31 Dec 2022: revenue $23.8M, net income -$28.2MQuarter to 31 Mar 2023: revenue $24.4M, net income -$28.5MQuarter to 31 Mar 2023: revenue $24.4M, net income -$28.5MQuarter to 30 Jun 2023: revenue $33.1M, net income -$25.3MQuarter to 30 Jun 2023: revenue $33.1M, net income -$25.3MQuarter to 30 Sep 2023: revenue $35.1M, net income -$24.6MQuarter to 30 Sep 2023: revenue $35.1M, net income -$24.6MQuarter to 31 Dec 2023: revenue $43.6M, net income -$27.5MQuarter to 31 Dec 2023: revenue $43.6M, net income -$27.5MQuarter to 31 Mar 2024: revenue $44.5M, net income -$26.0MQuarter to 31 Mar 2024: revenue $44.5M, net income -$26.0MQuarter to 30 Jun 2024: revenue $53.4M, net income -$25.6MQuarter to 30 Jun 2024: revenue $53.4M, net income -$25.6MQuarter to 30 Sep 2024: revenue $58.4M, net income -$21.0MQuarter to 30 Sep 2024: revenue $58.4M, net income -$21.0MQuarter to 31 Dec 2024: revenue $68.2M, net income -$18.9MQuarter to 31 Dec 2024: revenue $68.2M, net income -$18.9MQuarter to 31 Mar 2025: revenue $69.2M, net income -$24.7MQuarter to 31 Mar 2025: revenue $69.2M, net income -$24.7MQuarter to 30 Jun 2025: revenue $79.2M, net income -$19.6MQuarter to 30 Jun 2025: revenue $79.2M, net income -$19.6MQuarter to 30 Sep 2025: revenue $83.3M, net income -$21.4MQuarter to 30 Sep 2025: revenue $83.3M, net income -$21.4MQuarter to 31 Dec 2025: revenue $76.4M, net income -$29.8MQuarter to 31 Dec 2025: revenue $76.4M, net income -$29.8MQuarter to 31 Mar 2026: revenue $83.1M, net income -$31.6MQuarter to 31 Mar 2026: revenue $83.1M, net income -$31.6MQuarter to 30 Jun 2026: revenue $94.5M, net income -$26.9MQuarter to 30 Jun 2026: revenue $94.5M, net income -$26.9MQuarter to 30 Sep 2026: revenue $98.3M, net income -$26.5MQuarter to 30 Sep 2026: revenue $98.3M, net income -$26.5M
31 Dec 2021RevenueNet incomeNet losstallest bar $98.3M30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026$98.3M-$26.5M
30 Jun 2026$94.5M-$26.9M
31 Mar 2026$83.1M-$31.6M
31 Dec 2025$76.4M-$29.8M
30 Sep 2025$83.3M-$21.4M
30 Jun 2025$79.2M-$19.6M
31 Mar 2025$69.2M-$24.7M
31 Dec 2024$68.2M-$18.9M
30 Sep 2024$58.4M-$21.0M
30 Jun 2024$53.4M-$25.6M
31 Mar 2024$44.5M-$26.0M
31 Dec 2023$43.6M-$27.5M
30 Sep 2023$35.1M-$24.6M
30 Jun 2023$33.1M-$25.3M
31 Mar 2023$24.4M-$28.5M
31 Dec 2022$23.8M-$28.2M
30 Sep 2022$20.3M-$22.6M
30 Jun 2022$16.7M-$19.2M
31 Mar 2022$14.2M-$17.2M
31 Dec 2021$10.1M-$18.3M
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. $352.3M $299.9M
Revenue growthRevenue of the last 12 months compared with the 12 months before. +17% +13%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. -$114.9M -$84.6M
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). -$2.02 -$1.52
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. 64.7% 64.5% 60.5%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. -33.6% -30.9% -8.3%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. -32.6% -28.2% -10.1%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. -32.4% -26.3%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. -$85.1M -$79.7M
CashCash, cash equivalents and short-term investments on the latest balance sheet. $218.4M $294.3M
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. $51.8M $51.6M
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). -$166.6M (net cash) -$242.7M
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. 0.16 0.31
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. $5.72
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. loss 28.0
P/SPrice to sales: market cap divided by revenue of the last 12 months. 4.0 2.3
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. 3.6 2.5
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. 4.3 2.8

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
PROCEPT BioRoboticsPRCT (this company) $1.4Bloss4.0+17%-32.6%
Kestra Medical TechnologiesKMTS $1.5Bloss14.0+61%-140%
Inspire Medical SystemsINSP $1.6B15.81.8-0.2%11.4%
NovoCureNVCR $1.3Bloss1.7+13%-16.8%
Tandem Diabetes CareTNDM $1.2Bloss1.1+6.8%-4.6%
LeMaitre VascularLMAT $1.7B26.66.3+12%23.5%

Insider Buy/Sell Shares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.

-$115K

bought $0, sold $115K

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

-8.4%

229 13F filers vs 250

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

94%

54.4M shares held by 13F filers (30 Sep 2026) of 57.5M outstanding (29 Oct 2026)

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

14%

7.9M shares sold short (30 Oct 2026) of 57.5M outstanding (29 Oct 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

9.0

7.9M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

+4.8%

7.5M shares sold short in the report before, 7.9M on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

59%

59% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 57%

Open jobs Job postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.

–

We do not track this company's careers site yet.

Open jobs change How the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.

–

We do not track this company's careers site yet.

Employees Total staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.

–

No headcount in its annual reports in our data.

Visa hiring (foreign workers) Applications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.

-14%

18 vs 21 applications

Revenue growth Sales in the latest reported quarter compared with the same quarter a year earlier.

+18%

$98.3M vs $83.3M (quarter ended 30 Sep 2026)

Capital spending Money spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.

-77%

$667K vs $2.9M (quarter ended 30 Sep 2026)

Federal contracts Money the US government committed to the company in contracts and grants over the last 12 months.

–

No data for this company

Lobbying What the company reported spending on federal lobbying over the last four quarters.

$120K

4 quarters, $

Layoff notices Workers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).

–

No data for this company

News (7d) Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

4

4 articles in the last 7 days; its usual week has 3 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

1.3×

4 articles in the last 7 days; its usual week has 3.

Price $24.70 on 20 Nov 2026, -11% over 12 months (12-month range $16.69 to $36.10)

  • Sharp change
  • 8-K and other filings
  • Lobbying filing
Insider net buying (open market). Insiders bought a net $10.3M in the last 12 months (the 12 months before: -$19.8M).
H-1B/E-3 applications certified. H-1B/E-3 applications certified: 18 published in the last 12 months, -14% on the 12 months before.
Revenue per quarter. Revenue $98.3M in the latest quarter, +18% on a year earlier.
Capital spending per quarter. Capital spending $667K in the latest quarter, -77% on a year earlier.
Institutional holders (13F filers). 229 13F filers reported holding it in the latest 13F quarter, -0.9% on a year earlier.
Lobbying spend. Lobbying spend: $120K published in the last 12 months, +300% on the 12 months before.

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: federal obligations, workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
2 Oct 20268-K and other filingsDirector or officer change
2 Oct 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
6 Mar 20268-K and other filingsDirector or officer change
6 Mar 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
18 Sep 20258-K and other filingsDirector or officer change
16 Sep 2025Sharp changeShort interest spike: short interest spike, 8.4M vs usual 6.1M (2025-08-29); 1.4x the same period a year earlier
24 Jul 20258-K and other filingsDirector or officer change
24 Jul 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
18 Feb 2025Sharp changeMany funds opening a new position: many funds opening a new position, 51 vs usual 24.50 (2024-12-31); 2.0x the same period a year earlier
19 Nov 2024Sharp changeMany funds opening a new position: many funds opening a new position, 59 vs usual 23.50 (2024-09-30); 3.5x the same period a year earlier
20 Oct 2024Lobbying filinglobbying engagement terminated (FOLEY HOAG LLP)
20 Aug 2024Sharp changeMany funds opening a new position: many funds opening a new position, 46 vs usual 23.50 (2024-06-30); 2.0x the same period a year earlier
19 Jul 20248-K and other filingsDirector or officer change
19 Jul 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
19 Apr 20248-K and other filingsDirector or officer change
19 Apr 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
5 Mar 2024Sharp changeQuarterly capital spending jump: quarterly capital spending jump, 8.7M vs usual 1.2M (2023-12-31); 10.1x the same period a year earlier
7 Nov 2023Sharp changeQuarterly capital spending jump: quarterly capital spending jump, 5.8M vs usual 599K (2023-09-30); 3.8x the same period a year earlier
29 Aug 2023Sharp changeShort interest spike: short interest spike, 4.4M vs usual 2.7M (2023-08-15); 1.8x the same period a year earlier
1 Aug 2023Sharp changeQuarterly capital spending jump: quarterly capital spending jump, 5.4M vs usual 275K (2023-06-30); 24.6x the same period a year earlier
9 May 2023Sharp changeQuarterly capital spending jump: quarterly capital spending jump, 5.3M vs usual 164K (2023-03-31); 97.1x the same period a year earlier
11 Oct 20228-K and other filingsA major agreement ended
9 Aug 2022Sharp changeQuarterly revenue change: quarterly revenue change, 16.7M vs usual 8.5M (2022-06-30); 2.0x the same period a year earlier
4 Jan 20228-K and other filingsDirector or officer change
Insider net buying (open market)
Month from 1 Mar 2022: -$37.3M published
Month from 1 May 2022: -$24K published
Month from 1 Jun 2022: -$720K published
Month from 1 Dec 2022: -$1.8M published
Month from 1 Jan 2023: -$888K published
Month from 1 Mar 2023: -$1.8M published
Month from 1 Apr 2023: -$773K published
Month from 1 Jun 2023: -$795K published
Month from 1 Aug 2023: -$316K published
Month from 1 Nov 2023: -$805K published
Month from 1 Dec 2023: -$7.4M published
Month from 1 Jan 2024: -$1.5M published
Month from 1 Feb 2024: -$3.6M published
Month from 1 Mar 2024: -$2.1M published
Month from 1 May 2024: -$3.1M published
Month from 1 Jun 2024: -$2.4M published
Month from 1 Sep 2024: -$19.2M published
Month from 1 Oct 2024: -$1.8M published
Month from 1 Nov 2024: -$40.8M published
Month from 1 Dec 2024: -$7.9M published
Month from 1 Mar 2025: -$2.0M published
Month from 1 Jun 2025: -$10.7M published
Month from 1 Aug 2025: $785K published
Month from 1 Mar 2026: $9.9M published
Month from 1 Jun 2026: -$28K published
Month from 1 Aug 2026: $498K published
Month from 1 Sep 2026: -$22K published
Month from 1 Nov 2026: -$93K published
H-1B/E-3 applications certified
Quarter from 1 Jan 2022: 1 published
Quarter from 1 Apr 2022: 1 published
Quarter from 1 Jul 2022: 8 published
Quarter from 1 Oct 2022: 7 published
Quarter from 1 Jan 2023: 7 published
Quarter from 1 Apr 2023: 6 published
Quarter from 1 Jul 2023: 13 published
Quarter from 1 Oct 2023: 2 published
Quarter from 1 Jan 2024: 1 published
Quarter from 1 Apr 2024: 3 published
Quarter from 1 Jul 2024: 2 published
Quarter from 1 Oct 2024: 2 published
Quarter from 1 Jan 2025: 5 published
Quarter from 1 Apr 2025: 5 published
Quarter from 1 Jul 2025: 4 published
Quarter from 1 Oct 2025: 7 published
Quarter from 1 Jan 2026: 7 published
Quarter from 1 Apr 2026: 5 published
Quarter from 1 Jul 2026: 4 published
Quarter from 1 Oct 2026: 2 published
Revenue per quarter
Quarter ended 31 Dec 2020: $3.2M; public on 23 Mar 2022
Quarter ended 31 Mar 2021: $7.2M; public on 7 May 2022
Quarter ended 30 Jun 2021: $8.5M; public on 6 Aug 2022
Quarter ended 31 Dec 2021: $10.1M, +215% on a year earlier; public on 23 Mar 2022
Quarter ended 31 Mar 2022: $14.2M, +97% on a year earlier; public on 7 May 2022
Quarter ended 30 Jun 2022: $16.7M, +97% on a year earlier; public on 6 Aug 2022
Quarter ended 30 Sep 2022: $20.3M, +135% on a year earlier; public on 5 Nov 2022
Quarter ended 31 Dec 2022: $23.8M, +135% on a year earlier; public on 1 Mar 2023
Quarter ended 31 Mar 2023: $24.4M, +72% on a year earlier; public on 5 May 2023
Quarter ended 30 Jun 2023: $33.1M, +98% on a year earlier; public on 29 Jul 2023
Quarter ended 30 Sep 2023: $35.1M, +72% on a year earlier; public on 3 Nov 2023
Quarter ended 31 Dec 2023: $43.6M, +83% on a year earlier; public on 29 Feb 2024
Quarter ended 31 Mar 2024: $44.5M, +83% on a year earlier; public on 3 May 2024
Quarter ended 30 Jun 2024: $53.4M, +61% on a year earlier; public on 3 Aug 2024
Quarter ended 30 Sep 2024: $58.4M, +66% on a year earlier; public on 29 Oct 2024
Quarter ended 31 Dec 2024: $68.2M, +57% on a year earlier; public on 28 Feb 2025
Quarter ended 31 Mar 2025: $69.2M, +55% on a year earlier; public on 3 May 2025
Quarter ended 30 Jun 2025: $79.2M, +48% on a year earlier; public on 8 Aug 2025
Quarter ended 30 Sep 2025: $83.3M, +43% on a year earlier; public on 6 Nov 2025
Quarter ended 31 Dec 2025: $76.4M, +12% on a year earlier; public on 27 Feb 2026
Quarter ended 31 Mar 2026: $83.1M, +20% on a year earlier; public on 1 May 2026
Quarter ended 30 Jun 2026: $94.5M, +19% on a year earlier; public on 6 Aug 2026
Quarter ended 30 Sep 2026: $98.3M, +18% on a year earlier; public on 5 Nov 2026
Capital spending per quarter
Quarter ended 31 Dec 2020: $9K; public on 23 Mar 2022
Quarter ended 31 Mar 2021: $39K; public on 7 May 2022
Quarter ended 30 Jun 2021: $110K; public on 6 Aug 2022
Quarter ended 31 Dec 2021: $332K, +3589% on a year earlier; public on 23 Mar 2022
Quarter ended 31 Mar 2022: $55K, +41% on a year earlier; public on 7 May 2022
Quarter ended 30 Jun 2022: $218K, +98% on a year earlier; public on 6 Aug 2022
Quarter ended 30 Sep 2022: $1.5M, +1264% on a year earlier; public on 5 Nov 2022
Quarter ended 31 Dec 2022: $866K, +161% on a year earlier; public on 1 Mar 2023
Quarter ended 31 Mar 2023: $5.3M, +9607% on a year earlier; public on 5 May 2023
Quarter ended 30 Jun 2023: $5.4M, +2364% on a year earlier; public on 29 Jul 2023
Quarter ended 30 Sep 2023: $5.8M, +282% on a year earlier; public on 3 Nov 2023
Quarter ended 31 Dec 2023: $8.7M, +906% on a year earlier; public on 29 Feb 2024
Quarter ended 31 Mar 2024: $1.9M, -64% on a year earlier; public on 3 May 2024
Quarter ended 30 Jun 2024: $1.0M, -81% on a year earlier; public on 3 Aug 2024
Quarter ended 30 Sep 2024: $246K, -96% on a year earlier; public on 29 Oct 2024
Quarter ended 31 Dec 2024: $1.2M, -87% on a year earlier; public on 28 Feb 2025
Quarter ended 31 Mar 2025: $1.8M, -5.7% on a year earlier; public on 3 May 2025
Quarter ended 30 Jun 2025: $2.8M, +169% on a year earlier; public on 8 Aug 2025
Quarter ended 30 Sep 2025: $2.9M, +1066% on a year earlier; public on 6 Nov 2025
Quarter ended 31 Dec 2025: $1.9M, +58% on a year earlier; public on 27 Feb 2026
Quarter ended 31 Mar 2026: $2.9M, +59% on a year earlier; public on 1 May 2026
Quarter ended 30 Jun 2026: $3.0M, +5.4% on a year earlier; public on 6 Aug 2026
Quarter ended 30 Sep 2026: $667K, -77% on a year earlier; public on 5 Nov 2026
Institutional holders (13F filers)
31 Dec 2021 report: 57; public on 14 Feb 2022
31 Mar 2022 report: 54; public on 16 May 2022
30 Jun 2022 report: 88; public on 15 Aug 2022
30 Sep 2022 report: 94; public on 14 Nov 2022
31 Dec 2022 report: 111; public on 14 Feb 2023
31 Mar 2023 report: 111; public on 15 May 2023
30 Jun 2023 report: 114; public on 14 Aug 2023
30 Sep 2023 report: 119; public on 14 Nov 2023
31 Dec 2023 report: 137; public on 14 Feb 2024
31 Mar 2024 report: 156; public on 15 May 2024
30 Jun 2024 report: 193; public on 14 Aug 2024
30 Sep 2024 report: 237; public on 14 Nov 2024
31 Dec 2024 report: 273; public on 14 Feb 2025
31 Mar 2025 report: 269; public on 15 May 2025
30 Jun 2025 report: 260; public on 14 Aug 2025
30 Sep 2025 report: 231; public on 14 Nov 2025
31 Dec 2025 report: 251; public on 17 Feb 2026
31 Mar 2026 report: 248; public on 15 May 2026
30 Jun 2026 report: 250; public on 14 Aug 2026
30 Sep 2026 report: 229; public on 16 Nov 2026
Lobbying spend
Quarter from 1 Jan 2022: $27K published
Quarter from 1 Apr 2022: $27K published
Quarter from 1 Jul 2022: $27K published
Quarter from 1 Oct 2022: $27K published
Quarter from 1 Jan 2023: $27K published
Quarter from 1 Apr 2023: $27K published
Quarter from 1 Jul 2023: $27K published
Quarter from 1 Oct 2023: $27K published
Quarter from 1 Jan 2024: $27K published
Quarter from 1 Apr 2024: $27K published
Quarter from 1 Jul 2024: $27K published
Quarter from 1 Oct 2024: $27K published
Quarter from 1 Oct 2025: $30K published
Quarter from 1 Jan 2026: $30K published
Quarter from 1 Apr 2026: $30K published
Quarter from 1 Jul 2026: $30K published
Quarter from 1 Oct 2026: $30K published

What is unusual now

  • Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is revenue, quarter at $98.3M (30 Sep 2026), 1.3× its normal quarter; higher than 100% of its own history.
  • Insider net buying (open market): Insiders bought a net $10.3M in the last 12 months (the 12 months before: -$19.8M).
  • H-1B/E-3 applications certified: H-1B/E-3 applications certified: 18 published in the last 12 months, -14% on the 12 months before.
  • Revenue per quarter: Revenue $98.3M in the latest quarter, +18% on a year earlier.

Latest records

The names and amounts behind the totals, newest first

Insider trades

All 86 insider trades

Last 90 days: 4 sales, $115K; no purchases. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
6 Nov 2026Pooja SharmaChief Strat/Marketing OfficerSell4,710$19.71$93KForm 4
10 Sep 2026Kevin WatersEVP, CFOSell373$20.95$8KForm 4
10 Sep 2026Alaleh NouriEVP, CLO, CORP. SEC.Sell297$20.95$6KForm 4
10 Sep 2026Barry L TemplinEVP, Chief Technology OfficerSell373$20.95$8KForm 4
10 Aug 2026Larry L WoodPresident, CEOBuy23,900$20.85$498KForm 4
10 Jun 2026Barry L TemplinEVP, Chief Technology OfficerSell358$28.48$10KForm 4
10 Jun 2026Alaleh NouriEVP, CLO, CORP. SEC.Sell285$28.48$8KForm 4
10 Jun 2026Kevin WatersEVP, CFOSell357$28.48$10KForm 4

229 institutions reported shares at the end of Q3 2026, 94% of the shares outstanding; 24 opened a position, 48 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
BlackRock, Inc.4.8M8.42%$88.3M-23K-0.5%
T. Rowe Price Investment Management, Inc.3.3M5.70%+11K+0.3%
BNP PARIBAS ASSET MANAGEMENT Holding S.A.2.8M4.84%$50.8M-38K-1.3%
Vanguard Portfolio Management LLC2.5M4.28%$44.9M-61K-2.4%
Vanguard Capital Management LLC2.4M4.19%$44.0M-48K-2.0%
JPMorgan Chase & Co1.9M3.31%$34.8M+1.6M+581%
Frontier Capital Management Co LLC1.9M3.22%$33.8M+762K+70%
State Street Corp1.7M2.95%$30.9M+77K+4.8%
Geode Capital Management, LLC1.3M2.32%$24.3M-150K-10%
T. Rowe Price Associates Inc1.3M2.31%-4,281-0.3%

Company events

All 19 company events

In 12 months: 2 director or officer changes, 1 major agreement. Results releases and routine reports are left out.

FiledWhat happenedSource
2 Oct 2026Director or officer change8-K
24 Sep 2026Signed a major agreement8-K
5 Mar 2026Director or officer change8-K
18 Sep 2025Director or officer change8-K
24 Jul 2025Director or officer change8-K
19 Jul 2024Director or officer change8-K
19 Apr 2024Director or officer change8-K
1 Jun 2023Signed a major agreementSame filing: took on new debt8-K

Reported lobbying spend: $30K in Q3 2026, $30K in Q2 2026. Rows are lobbying firms hired or let go; amounts are reported per quarter, not per firm here.

DateChangeLobbying firmIssueSource
20 Sep 2024EndedFoley Hoag LLPfor Procept Biorobotics-Issues pertaining to Medicare coverage of medical device.Medicare/MedicaidFiling
4 Sep 2021NewFoley Hoag LLPfor Procept Biorobotics-Issues pertaining o Medicare coverage of medical devicesMedicare/MedicaidFiling
3 Sep 2021EndedPolsinelli PCfor Procept BioroboticsIssues pertaining to Medicare coverage of medical devicesMedicare/MedicaidFiling
3 Dec 2018NewPolsinelli PCfor Procept BioroboticsIssues pertaining to Medicare coverage of medical devices.Health issuesFiling

The 5 newest of 139 articles that name the company.

Timeline

Several things at once

Two or more unrelated kinds of records unusual within 30 days

29 Aug 2023confirmed

Confirmed across sources Filings + Financials and Short interest and volume

PROCEPT BioRobotics (PRCT): spent $5.4M on capital projects in the quarter ended 30 Jun 2023, 25× the same quarter last year, while it had 4.4M shares sold short in the 15 Aug 2023 report, 1.8× the same report last year. Two unrelated kinds of activity within 28 days.

  • Financials: Quarterly capital spending jump, became public on 1 Aug 2023
  • Short interest and volume: Short interest spike, became public on 25 Aug 2023
2021-06-30: $110K2021-09-30: $111K2021-12-31: $332K2022-03-31: $55K2022-06-30: $218K2022-09-30: $1.5M2022-12-31: $866K2023-03-31: $5.3M2023-06-30: $5.4M
The quarter ended 30 Jun 2023 against the 8 quarters before it. this quarterearliernormal: $275K
See the evidence (2 changes)

Financials: Quarterly capital spending jump became public on 1 Aug 2023

PROCEPT BioRobotics spent $5.4M on capital projects in the quarter ended 30 Jun 2023, 25× the same quarter last year.

This period
$5.4M (the quarter ended 30 Jun 2023)
Normal quarter (median of 8 earlier)
$275K
Typical spread (median absolute deviation)
$192K
How far from its usual level
+5.1
Same quarter last year
$218K
History used
911 days
2021-06-30: $110K2021-09-30: $111K2021-12-31: $332K2022-03-31: $55K2022-06-30: $218K2022-09-30: $1.5M2022-12-31: $866K2023-03-31: $5.3M2023-06-30: $5.4M
the quarter ended 30 Jun 20238 earlier quartersnormal: $275K

Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.

Check it at the source: SEC EDGAR quarterly reports.

Short interest and volume: Short interest spike became public on 25 Aug 2023

PROCEPT BioRobotics had 4.4M shares sold short in the 15 Aug 2023 report, 1.8× the same report last year.

This period
4.4M (the 15 Aug 2023 report)
Normal report (median of 24 earlier)
2.7M
Typical spread (median absolute deviation)
329K
How far from its usual level
+3.5
Same report last year
2.5M
History used
684 days
2022-08-15: 2.5M2022-08-31: 2.4M2022-09-15: 2.7M2022-09-30: 3.0M2022-10-14: 3.0M2022-10-31: 2.7M2022-11-15: 3.0M2022-11-30: 3.2M2022-12-15: 3.1M2022-12-30: 3.1M2023-01-13: 2.5M2023-01-31: 2.2M2023-02-15: 2.2M2023-02-28: 2.4M2023-03-15: 2.7M2023-03-31: 2.4M2023-04-14: 2.4M2023-04-28: 2.6M2023-05-15: 2.2M2023-05-31: 2.6M2023-06-15: 3.1M2023-06-30: 3.2M2023-07-14: 3.1M2023-07-31: 3.5M2023-08-15: 4.4M
the 15 Aug 2023 report24 earlier reportsnormal: 2.7M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

Timeline

Changes and notable records, by the date each became public

  1. 2 Oct 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  2. 2 Oct 2026Filings record

    Director or officer change

  3. 11 Aug 2026Insiders record

    Wood Larry L (President, CEO) bought 23,900 shares of PRCT ($498,315) (dated 10 Aug 2026)

  4. 10 Mar 2026Insiders record

    Desai Antal Rohit (director) bought 426,262 shares of PRCT ($10.5M) (dated 9 Mar 2026)

  5. 6 Mar 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  6. 6 Mar 2026Filings record

    Director or officer change (dated 5 Mar 2026)

  7. 18 Sep 2025Filings record

    Director or officer change

  8. 11 Sep 2025Short interest and volume change

    had 8.4M shares sold short in the 29 Aug 2025 report, 1.4× the same report last year.

    Same report last year: 6.0M; its normal report is 6.1M.

    See the evidence
    This period
    8.4M (the 29 Aug 2025 report)
    Normal report (median of 24 earlier)
    6.1M
    Typical spread (median absolute deviation)
    342K
    How far from its usual level
    +3.7
    Same report last year
    6.0M
    History used
    1,429 days
    2024-08-30: 6.0M2024-09-13: 5.7M2024-09-30: 5.5M2024-10-15: 6.7M2024-10-31: 5.9M2024-11-15: 6.4M2024-11-29: 6.1M2024-12-13: 6.2M2024-12-31: 6.9M2025-01-15: 7.1M2025-01-31: 6.0M2025-02-14: 5.7M2025-02-28: 5.1M2025-03-14: 5.8M2025-03-31: 6.3M2025-04-15: 6.1M2025-04-30: 5.8M2025-05-15: 5.9M2025-05-30: 6.1M2025-06-13: 6.7M2025-06-30: 6.8M2025-07-15: 6.8M2025-07-31: 7.1M2025-08-15: 8.1M2025-08-29: 8.4M
    the 29 Aug 2025 report24 earlier reportsnormal: 6.1M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  9. 15 Aug 2025Insiders record

    MOLL FREDERIC H (director) bought 20,000 shares of PRCT ($785,200) (dated 14 Aug 2025)

  10. 24 Jul 2025Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  11. 24 Jul 2025Filings record

    Director or officer change

  12. 14 Feb 2025Institutional holdings change

    saw 51 13F filers open a new position in the quarter ended 31 Dec 2024, 2.0× the same quarter last year.

    Same quarter last year: 25; its normal quarter is 24.5.

    See the evidence
    This period
    51 (the quarter ended 31 Dec 2024)
    Normal quarter (median of 8 earlier)
    24.5
    Typical spread (median absolute deviation)
    4
    How far from its usual level
    +4.5
    Same quarter last year
    25
    History used
    1,188 days
    2022-12-31: 242023-03-31: 202023-06-30: 232023-09-30: 172023-12-31: 252024-03-31: 282024-06-30: 462024-09-30: 592024-12-31: 51
    the quarter ended 31 Dec 20248 earlier quartersnormal: 24.5

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  13. 14 Nov 2024Institutional holdings change

    saw 59 13F filers open a new position in the quarter ended 30 Sep 2024, 3.5× the same quarter last year.

    Same quarter last year: 17; its normal quarter is 23.5.

    See the evidence
    This period
    59 (the quarter ended 30 Sep 2024)
    Normal quarter (median of 8 earlier)
    23.5
    Typical spread (median absolute deviation)
    4
    How far from its usual level
    +6.0
    Same quarter last year
    17
    History used
    1,096 days
    2022-09-30: 152022-12-31: 242023-03-31: 202023-06-30: 232023-09-30: 172023-12-31: 252024-03-31: 282024-06-30: 462024-09-30: 59
    the quarter ended 30 Sep 20248 earlier quartersnormal: 23.5

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  14. 20 Oct 2024Lobbying record

    PROCEPT BIOROBOTICS: lobbying engagement terminated (FOLEY HOAG LLP) (dated 20 Sep 2024)

  15. 14 Aug 2024Institutional holdings change

    saw 46 13F filers open a new position in the quarter ended 30 Jun 2024, 2.0× the same quarter last year.

    Same quarter last year: 23; its normal quarter is 23.5.

    See the evidence
    This period
    46 (the quarter ended 30 Jun 2024)
    Normal quarter (median of 8 earlier)
    23.5
    Typical spread (median absolute deviation)
    4
    How far from its usual level
    +3.8
    Same quarter last year
    23
    History used
    1,004 days
    2022-06-30: 402022-09-30: 152022-12-31: 242023-03-31: 202023-06-30: 232023-09-30: 172023-12-31: 252024-03-31: 282024-06-30: 46
    the quarter ended 30 Jun 20248 earlier quartersnormal: 23.5

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  16. 19 Jul 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  17. 19 Jul 2024Filings record

    Director or officer change

  18. 19 Apr 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  19. 19 Apr 2024Filings record

    Director or officer change

  20. 5 Mar 2024Financials change

    spent $8.7M on capital projects in the quarter ended 31 Dec 2023, 10× the same quarter last year.

    Same quarter last year: $866K; its normal quarter is $1.2M.

    See the evidence
    This period
    $8.7M (the quarter ended 31 Dec 2023)
    Normal quarter (median of 8 earlier)
    $1.2M
    Typical spread (median absolute deviation)
    $1.1M
    How far from its usual level
    +4.8
    Same quarter last year
    $866K
    History used
    1,095 days
    2021-12-31: $332K2022-03-31: $55K2022-06-30: $218K2022-09-30: $1.5M2022-12-31: $866K2023-03-31: $5.3M2023-06-30: $5.4M2023-09-30: $5.8M2023-12-31: $8.7M
    the quarter ended 31 Dec 20238 earlier quartersnormal: $1.2M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  21. 7 Nov 2023Financials change

    spent $5.8M on capital projects in the quarter ended 30 Sep 2023, 3.8× the same quarter last year.

    Same quarter last year: $1.5M; its normal quarter is $599K.

    See the evidence
    This period
    $5.8M (the quarter ended 30 Sep 2023)
    Normal quarter (median of 8 earlier)
    $599K
    Typical spread (median absolute deviation)
    $516K
    How far from its usual level
    +5.2
    Same quarter last year
    $1.5M
    History used
    1,003 days
    2021-09-30: $111K2021-12-31: $332K2022-03-31: $55K2022-06-30: $218K2022-09-30: $1.5M2022-12-31: $866K2023-03-31: $5.3M2023-06-30: $5.4M2023-09-30: $5.8M
    the quarter ended 30 Sep 20238 earlier quartersnormal: $599K

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  22. 29 Aug 2023several at once

    spent $5.4M on capital projects in the quarter ended 30 Jun 2023, 25× the same quarter last year, while it had 4.4M shares sold short in the 15 Aug 2023 report, 1.8× the same report last year. Two unrelated kinds of activity within 28 days.

    See the evidence (2 changes)

    Financials: Quarterly capital spending jump became public on 1 Aug 2023

    PROCEPT BioRobotics spent $5.4M on capital projects in the quarter ended 30 Jun 2023, 25× the same quarter last year.

    This period
    $5.4M (the quarter ended 30 Jun 2023)
    Normal quarter (median of 8 earlier)
    $275K
    Typical spread (median absolute deviation)
    $192K
    How far from its usual level
    +5.1
    Same quarter last year
    $218K
    History used
    911 days
    2021-06-30: $110K2021-09-30: $111K2021-12-31: $332K2022-03-31: $55K2022-06-30: $218K2022-09-30: $1.5M2022-12-31: $866K2023-03-31: $5.3M2023-06-30: $5.4M
    the quarter ended 30 Jun 20238 earlier quartersnormal: $275K

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.

    Check it at the source: SEC EDGAR quarterly reports.

    Short interest and volume: Short interest spike became public on 25 Aug 2023

    PROCEPT BioRobotics had 4.4M shares sold short in the 15 Aug 2023 report, 1.8× the same report last year.

    This period
    4.4M (the 15 Aug 2023 report)
    Normal report (median of 24 earlier)
    2.7M
    Typical spread (median absolute deviation)
    329K
    How far from its usual level
    +3.5
    Same report last year
    2.5M
    History used
    684 days
    2022-08-15: 2.5M2022-08-31: 2.4M2022-09-15: 2.7M2022-09-30: 3.0M2022-10-14: 3.0M2022-10-31: 2.7M2022-11-15: 3.0M2022-11-30: 3.2M2022-12-15: 3.1M2022-12-30: 3.1M2023-01-13: 2.5M2023-01-31: 2.2M2023-02-15: 2.2M2023-02-28: 2.4M2023-03-15: 2.7M2023-03-31: 2.4M2023-04-14: 2.4M2023-04-28: 2.6M2023-05-15: 2.2M2023-05-31: 2.6M2023-06-15: 3.1M2023-06-30: 3.2M2023-07-14: 3.1M2023-07-31: 3.5M2023-08-15: 4.4M
    the 15 Aug 2023 report24 earlier reportsnormal: 2.7M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

  23. 25 Aug 2023Short interest and volume change

    had 4.4M shares sold short in the 15 Aug 2023 report, 1.8× the same report last year.

    Same report last year: 2.5M; its normal report is 2.7M.

    See the evidence
    This period
    4.4M (the 15 Aug 2023 report)
    Normal report (median of 24 earlier)
    2.7M
    Typical spread (median absolute deviation)
    329K
    How far from its usual level
    +3.5
    Same report last year
    2.5M
    History used
    684 days
    2022-08-15: 2.5M2022-08-31: 2.4M2022-09-15: 2.7M2022-09-30: 3.0M2022-10-14: 3.0M2022-10-31: 2.7M2022-11-15: 3.0M2022-11-30: 3.2M2022-12-15: 3.1M2022-12-30: 3.1M2023-01-13: 2.5M2023-01-31: 2.2M2023-02-15: 2.2M2023-02-28: 2.4M2023-03-15: 2.7M2023-03-31: 2.4M2023-04-14: 2.4M2023-04-28: 2.6M2023-05-15: 2.2M2023-05-31: 2.6M2023-06-15: 3.1M2023-06-30: 3.2M2023-07-14: 3.1M2023-07-31: 3.5M2023-08-15: 4.4M
    the 15 Aug 2023 report24 earlier reportsnormal: 2.7M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  24. 1 Aug 2023Financials change

    spent $5.4M on capital projects in the quarter ended 30 Jun 2023, 25× the same quarter last year.

    Same quarter last year: $218K; its normal quarter is $275K.

    See the evidence
    This period
    $5.4M (the quarter ended 30 Jun 2023)
    Normal quarter (median of 8 earlier)
    $275K
    Typical spread (median absolute deviation)
    $192K
    How far from its usual level
    +5.1
    Same quarter last year
    $218K
    History used
    911 days
    2021-06-30: $110K2021-09-30: $111K2021-12-31: $332K2022-03-31: $55K2022-06-30: $218K2022-09-30: $1.5M2022-12-31: $866K2023-03-31: $5.3M2023-06-30: $5.4M
    the quarter ended 30 Jun 20238 earlier quartersnormal: $275K

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  25. 9 May 2023Financials change

    spent $5.3M on capital projects in the quarter ended 31 Mar 2023, 97× the same quarter last year.

    Same quarter last year: $55K; its normal quarter is $164K.

    See the evidence
    This period
    $5.3M (the quarter ended 31 Mar 2023)
    Normal quarter (median of 8 earlier)
    $164K
    Typical spread (median absolute deviation)
    $118K
    How far from its usual level
    +5.2
    Same quarter last year
    $55K
    History used
    820 days
    2021-03-31: $39K2021-06-30: $110K2021-09-30: $111K2021-12-31: $332K2022-03-31: $55K2022-06-30: $218K2022-09-30: $1.5M2022-12-31: $866K2023-03-31: $5.3M
    the quarter ended 31 Mar 20238 earlier quartersnormal: $164K

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  26. 11 Oct 2022Filings record

    A major agreement ended

  27. 9 Aug 2022Financials change

    reported revenue of $16.7M for the quarter ended 30 Jun 2022, 2.0× the same quarter last year.

    Same quarter last year: $8.5M; its normal quarter is $8.5M.

    See the evidence
    This period
    $16.7M (the quarter ended 30 Jun 2022)
    Normal quarter (median of 7 earlier)
    $8.5M
    Typical spread (median absolute deviation)
    $1.7M
    How far from its usual level
    +3.3
    Same quarter last year
    $8.5M
    History used
    638 days
    2020-09-30: $2.1M2020-12-31: $3.2M2021-03-31: $7.2M2021-06-30: $8.5M2021-09-30: $8.7M2021-12-31: $10.1M2022-03-31: $14.2M2022-06-30: $16.7M
    the quarter ended 30 Jun 20227 earlier quartersnormal: $8.5M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  28. 15 Mar 2022Insiders record

    Wood Morgan Colby (director) bought 940 shares of PRCT ($22,964) (dated 14 Mar 2022)

  29. 4 Jan 2022Filings record

    Director or officer change

  30. 30 Oct 2021Lobbying record

    PROCEPT BIOROBOTICS: new lobbying registration (FOLEY HOAG LLP) (dated 4 Sep 2021)

  31. 26 Oct 2021Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  32. 26 Oct 2021Filings record

    Director or officer change

  33. 23 Sep 2021Insiders record

    Wood Morgan Colby (director) bought 3,200 shares of PRCT ($80,000) [amended] (dated 22 Sep 2021)

  34. 22 Sep 2021Insiders change

    had 6 insiders buy $35.5M of its shares on the open market within 30 days (6 filings).

    Who bought: Moll Frederic H, Krummel Thomas M, Harris Taylor C., Wood Morgan Colby.

    See the evidence (6 source records)
    Independent buyers
    6
    Purchase filings (Form 4, code P)
    6
    Total bought
    $35.5M
    Window
    23 Aug 2021 to 22 Sep 2021

    Fires when at least 3 independent insiders (joint filers count once) buy on the open market in 30 days, in at least 2 filings, for $100K or more in total; amendments do not count.

  35. 22 Sep 2021Insiders record

    HALVORSEN OLE ANDREAS (ten percent owner) and 7 other(s) bought 400,000 shares of PRCT ($14.0M) (dated 21 Sep 2021)

  36. 22 Sep 2021Insiders record

    Wood Morgan Colby (director) bought 6,800 shares of PRCT ($170,000) (dated 21 Sep 2021)

  37. 22 Sep 2021Insiders record

    Desai Antal Rohit (director) bought 440,000 shares of PRCT [same transaction as an earlier filing] (dated 21 Sep 2021)

  38. 22 Sep 2021Insiders record

    McGaughy R Kent Jr (ten percent owner) and 2 other(s) bought 440,000 shares of PRCT ($11.0M) (dated 21 Sep 2021)

  39. 22 Sep 2021Insiders record

    Harris Taylor C. (director) bought 10,000 shares of PRCT ($250,000) (dated 21 Sep 2021)

  40. 22 Sep 2021Insiders record

    Krummel Thomas M (director) bought 5,000 shares of PRCT ($125,000) (dated 21 Sep 2021)

Showing the newest 40 of 50 entries; narrow the window or the kind of data to see older ones.

Not listed: 126 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0001588978
Ticker
PRCT
Domain
procept-biorobotics.com
Employer name
PROCEPT BIOROBOTICS CORPORATION (1 unverified)
Hq location
CA|SAN JOSE|95134 (1 unverified)
Lobbying client
procept biorobotics
Name
PROCEPT BioRobotics Corporation, PROCEPT BioRobotics UK Ltd
  • DOL H-1B labor condition applications and PERM certifications387 data points10 Feb 2020 to 14 Sep 2026
  • Federal lobbying disclosures (LDA)4 records, 86 data points3 Dec 2018 to 30 Sep 2026
  • SEC Form 13F institutional holdings189 data points30 Sep 2021 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)67 records28 Aug 2017 to 4 Nov 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)464 data points31 Dec 2019 to 29 Oct 2026
  • SEC Form 4 insider transactions86 records, 196 data points21 Sep 2021 to 6 Nov 2026
  • FINRA short interest (twice monthly)365 data points30 Sep 2021 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)2606 data points15 Sep 2021 to 20 Nov 2026